Gastrointestinal Oncology Program

University Hospitals Seidman Cancer Center

Amitabh Chak, MD, Gastroenterology 216-844-3217,
Jennifer Dorth, MD, Discipline Lead, Radiation Oncology 216-286-3903,
Jennifer Eads, MD, Upper GI Disease Team Leader, Medical Oncology 216-844-6003,
Jeffrey Hardacre, MD, Discipline Lead, Surgical Oncology 216-844-7047,
Philip Linden, MD, Esophageal Surgery 216-844-0065,

Please call Jeanie Wyckhouse, New Patient Access Coordinator, at 216-844-5020 or email
For hospital transfers, please call 216-844-1111.

Conditions Treated

  • Esophagogastric cancers, including Barrett’s esophagus
  • Biliary cancers
  • Pancreatic cancers: pancreatic adenocarcinoma, pancreatic cystic neoplasms, pancreatic neuroendocrine tumors and rare pancreatic tumors
  • Small intestinal cancers
  • Colorectal cancers
  • Anal cancers
  • Gastrointestinal stromal tumors
  • Neuroendocrine cancers

Procedures and Therapies

  • Endoscopic ultrasound, endoscopic mucosal resection and endoscopic submucosal dissection for the staging and treatment of early esophageal cancers
  • Noninvasive treatments (stenting, robotic and laparoscopic procedures, transanal resections)
  • Liver-directed therapies, including resection of metastases, surgical ablation, transarterial chemoembolization, radioembolization and percutaneous microwave ablation
  • Colo-anal reconstruction/sphincter-sparing surgery
  • Enhanced recovery programs following colorectal surgery
  • Radiation therapy, including proton beam therapy, IMRT and MR planning, and intraoperative radiation
  • Chemotherapy and immunotherapy, including clinical trials

Distinguishing Features

  • Part of NCI-designated Case Comprehensive Cancer Center
  • Multidisciplinary consultation and disease-specific tumor boards
  • First in Northeast Ohio to perform minimally invasive esophagectomy
  • Lowest esophagectomy mortality rate in the nation
  • One of three NCI Barrett’s Esophagus Translational Research Network centers, via Case Western Reserve University
  • Innovative clinical trials of new treatments
  • One of six National Cancer Institute Specialized Programs of Research Excellence (SPORE) centers for gastrointestinal cancers in the U.S., via Case Western Reserve University
  • National leadership in clinical pathway development
  • Noninvasive diagnostic technology using new imaging methodologies
  • First Proton Therapy Center in Ohio
  • Genetic analysis of tumors to guide personalized therapy
  • Genetic risk assessment to guide preventive strategies in cancer-prone families
  • Supportive and Integrative Oncology program
  • Specialized Adolescent and Young Adult (AYA) cancer program